Holocene Advisors LP Has $125.77 Million Position in CVS Health Corporation $CVS

Holocene Advisors LP lessened its holdings in CVS Health Corporation (NYSE:CVS) by 29.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,668,227 shares of the pharmacy operator’s stock after selling 705,715 shares during the period. Holocene Advisors LP’s holdings in CVS Health were worth $125,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. bought a new position in CVS Health during the second quarter worth about $1,651,000. Fiera Capital Corp grew its stake in shares of CVS Health by 17.2% in the 2nd quarter. Fiera Capital Corp now owns 4,771 shares of the pharmacy operator’s stock valued at $329,000 after purchasing an additional 701 shares during the period. Foundations Investment Advisors LLC raised its holdings in shares of CVS Health by 13.3% in the 2nd quarter. Foundations Investment Advisors LLC now owns 9,333 shares of the pharmacy operator’s stock worth $644,000 after buying an additional 1,096 shares in the last quarter. Empower Advisory Group LLC lifted its position in shares of CVS Health by 90.9% during the 2nd quarter. Empower Advisory Group LLC now owns 12,387 shares of the pharmacy operator’s stock worth $854,000 after buying an additional 5,897 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of CVS Health by 7.6% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 310,253 shares of the pharmacy operator’s stock worth $21,401,000 after buying an additional 21,925 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Stock Up 0.1%

Shares of NYSE:CVS opened at $76.14 on Monday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. The stock has a market cap of $96.87 billion, a price-to-earnings ratio of 55.17, a P/E/G ratio of 0.79 and a beta of 0.49. The company has a 50 day moving average of $78.17 and a 200-day moving average of $77.83. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. During the same period in the prior year, the business posted $1.19 earnings per share. CVS Health’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is currently 192.75%.

Analysts Set New Price Targets

A number of analysts have weighed in on CVS shares. Leerink Partners reiterated an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. JPMorgan Chase & Co. boosted their target price on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Bank of America lowered their target price on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, January 27th. Mizuho lifted their price target on shares of CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 29th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.